Improving Prediction of Ischemic Cardiovascular Disease Using Apolipoprotein B: the Copenhagen City Heart Study

This Copenhagen study is one of the cornerstone pieces of evidence behind the argument that apolipoprotein B is a better risk marker than LDL cholesterol — measured not in a select clinic but in the general population.

Tracking more than 9,000 community-dwelling adults, the investigators found that apoB strongly and independently predicted ischemic heart events in both men and women, with the highest tertile carrying up to 2.6 times the risk. The decisive comparison was head-to-head: apoB outperformed LDL cholesterol as a predictor of heart disease, myocardial infarction, and ischemic events alike, with statistically significant superiority. In high-risk subgroups, elevated apoB added an absolute 10-year risk increment of 11 to 15 percentage points.

The reasoning behind the result is the recurring theme of lipid science: apoB counts every atherogenic particle, while LDL cholesterol measures only the cholesterol they happen to carry — and when the two diverge, the particle count wins. This study supplied early, high-quality population evidence for that claim.

We rate the evidence strong. It is a large, well-conducted cohort from a respected research group, advancing the case for apoB that later consensus statements would formalize.